Accelerate Diagnostics Inc. (NASDAQ:AXDX) was down 5.9% during trading on Wednesday . The company traded as low as $20.10 and last traded at $20.70, with a volume of 339,586 shares trading hands. The stock had previously closed at $22.00.

A number of equities research analysts recently commented on AXDX shares. BTIG Research reissued a “buy” rating and set a $26.00 target price on shares of Accelerate Diagnostics in a research report on Wednesday, June 15th. Zacks Investment Research cut shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Wednesday, July 13th. JPMorgan Chase & Co. raised their price target on shares of Accelerate Diagnostics from $17.00 to $25.00 and gave the stock an “overweight” rating in a report on Tuesday. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $25.00 price target on shares of Accelerate Diagnostics in a report on Monday, May 16th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $25.33.

The stock has a 50-day moving average price of $18.22 and a 200-day moving average price of $14.36. The company’s market capitalization is $1.06 billion.

In other Accelerate Diagnostics news, Director Jack W. Schuler acquired 11,511 shares of the company’s stock in a transaction that occurred on Monday, May 16th. The stock was purchased at an average price of $11.91 per share, for a total transaction of $137,096.01. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jack W. Schuler acquired 101,272 shares of the company’s stock in a transaction that occurred on Thursday, June 9th. The stock was acquired at an average price of $14.14 per share, with a total value of $1,431,986.08. The disclosure for this purchase can be found here.

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.